{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lu Q"],"funding":["Major scientific and technological achievements transformation project, Ningxia Hui Autonomous Region","Science and Technology Department of Sichuan Province, P. R. China","CAMS Innovation Fund for Medical Science (CIFMS)","CAMS Innovation Fund for Medical Science","the 1·3·5 project for disciplines of excellence, West China Hospital, Sichuan University","National Natural Science Foundation of China","Achievement Transformation Project","the Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences","the Frontiers Medical Center, Tianfu Jincheng Laboratory Foundation"],"pagination":["279"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11112799"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(1)"],"pubmed_abstract":["Background
BCMA-directed autologous chimeric antigen receptor T (CAR-T) cells have shown excellent clinical efficacy in relapsed or refractory multiple myeloma (RRMM), however, the current preparation process for autologous CAR-T cells is complicated and costly. Moreover, the upregulation of CD47 expression has been observed in multiple myeloma, and anti-CD47 antibodies have shown remarkable results in clinical trials. Therefore, we focus on the development of BCMA/CD47-directed universal CAR-T (UCAR-T) cells to improve these limitations.Methods
In this study, we employed phage display technology to screen nanobodies against BCMA and CD47 protein, and determined the characterization of nanobodies. Furthermore, we simultaneously disrupted the endogenous TRAC and B2M genes of"],"journal":["Journal of nanobiotechnology"],"pubmed_title":["BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma."],"pmcid":["PMC11112799"],"funding_grant_id":["2021‐I2M‐5‐075","CGZH21001","2021-I2M-5-075","TFJC2023010006","82073404","2022CJE09013","ZYJC21003","2019RU067","2022NSFSC0847"],"pubmed_authors":["Li H","Wu Z","Tong A","Zhu Z","Zhang Z","Yang D","Lu Q"],"additional_accession":[]},"is_claimable":false,"name":"BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma.","description":"Background
BCMA-directed autologous chimeric antigen receptor T (CAR-T) cells have shown excellent clinical efficacy in relapsed or refractory multiple myeloma (RRMM), however, the current preparation process for autologous CAR-T cells is complicated and costly. Moreover, the upregulation of CD47 expression has been observed in multiple myeloma, and anti-CD47 antibodies have shown remarkable results in clinical trials. Therefore, we focus on the development of BCMA/CD47-directed universal CAR-T (UCAR-T) cells to improve these limitations.Methods
In this study, we employed phage display technology to screen nanobodies against BCMA and CD47 protein, and determined the characterization of nanobodies. Furthermore, we simultaneously disrupted the endogenous TRAC and B2M genes of","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-05-29T11:24:51.187Z","creation":"2026-04-08T04:27:05.347Z"},"accession":"S-EPMC11112799","cross_references":{"pubmed":["38783333"],"doi":["10.1186/s12951-024-02512-6"]}}